HLN: haleon.com EV/EBITDA Multiple
Haleon plc faces a debt burden following its spin-off from GSK and legal claims regarding Zantac, risking market share due to cheap generics. On GURU.Markets, the business's EV/EBITDA multiple helps identify a fundamental bottom, where 12.74 records fresh values. Efficient wholesale delivery to pharmacies reduces costs, while internal brand portfolio optimization replaces active asset acquisitions.
Comprehensive metric breakdowns and analytics for haleon.com (HLN)
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- debt and solvency information:
- financial results and valuation multiples details:
HLN - Company Net Income|Expected Profit Haleon plc|HLN - Price to Earnings Multiple|Projected Price to Earnings Haleon plc|HLN - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Corp|HLN - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Haleon|HLN - Earnings per share for the last twelve months|Quarterly EPS earnings growth haleon.com|HLN - Net earnings per share growth this year|Earnings growth forecast for next year Haleon plc
- revenue and sales details:
Fundamental company analysis:HLN (Haleon Group)
For Haleon plc, which is focused on reducing debt load and internal optimization, this multiple serves as a tool for assessing market value relative to operating profit. The metric correlates enterprise value (EV) with EBITDA, excluding the impact of taxes and depreciation to reveal the actual efficiency of assets. By analyzing the historical EV/EBITDA trend of the company on the GURU.Markets platform, an investor can track the business valuation dynamics. The current value of 12.74 makes it possible to determine whether the asset is overvalued or remains in a zone of fundamental undervaluation.
Who Haleon plc competes with
Kenvue Corp - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio VRNA (Verona Pharma Inc.)|Jyong Biotech Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation LGND (ligand.com)|AMRX: EV/EBITDA Multiple|Company Value to EBITDA Perrigo Company PLC (PRGO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alvotech Corp|LQDA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GLPG|ANIP (anipharmaceuticals.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MNKD (MannKind)|EV/EBITDA Multiple Amphastar Pharmaceuticals Inc AMPH|PCRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SPRY: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TBPH: EV/EBITDA Multiple|Company Value to EBITDA aquestive.com (AQST)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scPharmaceuticals, Inc.|Company Value to EBITDA Tectonic TECX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tonix Pharmaceuticals Inc. (TNXP)|sxtchina.com - Enterprise Value to Operating Income Before Depreciation|Eupraxia Pharmaceuticals Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHST|EXOZ - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ORMP|enterabio.com (ENTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|HYFT (MindWalk Therapeutics) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cumberlandpharma.com (CPIX)|EV/EBITDA Multiple QNTM|FGEN (FibroGen Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|Rani Therapeutics Holdings - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RLYB (Rallybio Corporation) - Enterprise Value to Operating Income Before Depreciation|lexariabioscience.com (LEXX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PULM (Pulmatrix Inc)|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|APM: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple impactbiomedinc.com (IBO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Altamira Therapeutics (CYTO) - Enterprise Value to EBITDA Ratio|LIPO: EV/EBITDA Multiple|optinose.com (OPTN) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PIRS|PROC: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI - Company Value to EBITDA|Acelyrin, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TFFP (tffpharma.com)
